Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.aohep.2020.09.015 http://scihub22266oqcxt.onion/10.1016/j.aohep.2020.09.015 33099028!7577265!33099028     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33099028&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Ann+Hepatol 2021 ; 20 (?): 100271 Nephropedia Template TP {{tp|p=33099028|t=2021. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19) |pdf=|usr=}}{{33099028}} gab.com Text Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19) JO: Ann Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=33099028 #FOAvip INTRODUCTION AND OBJECTIVES: Liver function tests (LFT) abnormalities are reported in up to 50% of COVID-19 patients, and metabolic comorbidities are associated with poorer outcomes. The aim of the study was to determine the prevalence of liver steatosis and fibrosis in patients with COVID-19 and their association with clinical outcomes. MATERIAL AND METHODS: Retrospective study in hospitalized COVID-19 patients was conducted. The risk for liver steatosis was estimated by HSI > 36, and risk for advanced liver fibrosis with APRI > 1.0, NAFLD FS > 0.675 and/or FIB-4 > 3.25. Clinical outcomes were admission to Intensive Care Unit (ICU) and mortality. RESULTS: Of 155 patients, 71.6% were male (n = 111), and 28.4% (n = 44) were obese. Abnormal LFT were present in 96.8% (n = 150), prevalence of steatosis was 42.6% (n = 66) and of significative liver fibrosis was 44.5% (n = 69). Liver fibrosis by FIB-4 was associated with risk of ICU admission (OR 1.74 [95%CI 1.74-2.68; p = 0.023]) and mortality (OR 6.45 [95%CI 2.01-20.83, p = 0.002]); no independent associations were found. CONCLUSIONS: The prevalence of steatosis and significant liver fibrosis was high in COVID-19 patients but was not associated with clinical outcomes. Twit Text FOAVip Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19) ????Ann Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=33099028 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33099028 #FOAvip English Wikipedia <ref>{{Cite pmid|33099028}}</ref> Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19) #MMPMID33099028 Lopez-Mendez I; Aquino-Matus J; Gall SM; Prieto-Nava JD; Juarez-Hernandez E; Uribe M; Castro-Narro G Ann Hepatol 2021[Jan]; 20 (?): 100271 PMID33099028show ga INTRODUCTION AND OBJECTIVES: Liver function tests (LFT) abnormalities are reported in up to 50% of COVID-19 patients, and metabolic comorbidities are associated with poorer outcomes. The aim of the study was to determine the prevalence of liver steatosis and fibrosis in patients with COVID-19 and their association with clinical outcomes. MATERIAL AND METHODS: Retrospective study in hospitalized COVID-19 patients was conducted. The risk for liver steatosis was estimated by HSI > 36, and risk for advanced liver fibrosis with APRI > 1.0, NAFLD FS > 0.675 and/or FIB-4 > 3.25. Clinical outcomes were admission to Intensive Care Unit (ICU) and mortality. RESULTS: Of 155 patients, 71.6% were male (n = 111), and 28.4% (n = 44) were obese. Abnormal LFT were present in 96.8% (n = 150), prevalence of steatosis was 42.6% (n = 66) and of significative liver fibrosis was 44.5% (n = 69). Liver fibrosis by FIB-4 was associated with risk of ICU admission (OR 1.74 [95%CI 1.74-2.68; p = 0.023]) and mortality (OR 6.45 [95%CI 2.01-20.83, p = 0.002]); no independent associations were found. CONCLUSIONS: The prevalence of steatosis and significant liver fibrosis was high in COVID-19 patients but was not associated with clinical outcomes. |Adult[MESH] |Alanine Transaminase/blood[MESH] |Aspartate Aminotransferases/blood[MESH] |Biomarkers/blood[MESH] |COVID-19/*epidemiology[MESH] |Comorbidity[MESH] |Cross-Sectional Studies[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Humans[MESH] |Intensive Care Units/*statistics & numerical data[MESH] |Liver Cirrhosis/blood/diagnosis/*epidemiology[MESH] |Male[MESH] |Mexico/epidemiology[MESH] |Middle Aged[MESH] |Non-alcoholic Fatty Liver Disease/blood/diagnosis/*epidemiology[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH]Association of liver steatosis and fibrosis with clinical outcomes in (epmc).pdf DeepDyve Pubget Overpricing